An interventional study of Bevacizumab Intravitreal Injection and Triamcinolone Acetonide Injection in Diabetic Macular Edema, sponsored by Muhammad Aamir Latif. Completed at 1 site in Pakistan. Open to participants aged 25 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-11-12.
Sponsored by Muhammad Aamir Latif · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 26 studies testing Triamcinolone Acetonide in Macular Edema — 1 open to participants now, 1 under way, none of them phase 3. Triamcinolone Acetonide · Macular Edema.
Among the 26 studies testing Triamcinolone Acetonide in Macular Edema, this one is the 15th largest by enrollment of the 25 interventional ones that give a count, is the only one that started in 2025, is one of 4 with no phase, and was the 26th registered.
758 studies on the registry are indexed under Macular Edema; 66 are open to participants now.
Browse Macular Edema studies →1 of the 26 studies testing Triamcinolone Acetonide in Macular Edema is open now, in 1 country. Recruiting first, the newest first:
Tanta University · Sites in Egypt
Healthy volunteers
By country, each count listing its studies:
Triamcinolone Acetonide: first FDA approval 1958 (TRIAMCINOLONE ACETONIDE). What it is approved for, and how studies give it, is on its page →
Of the 44 Macular Edema studies recruiting now, 31 (70%) set no upper age limit and 7 (16%) stop at 75 or younger; 1 takes children under 18; 2 take healthy volunteers.
This study: 25 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
26 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 8 · Phase 3 10 · Phase 4 1
First in 2002; this study’s year is marked. 1 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 46 is below the median of 56 across 586 interventional studies indexed under Macular Edema.
Median enrollment 75 across the 25 interventional studies. Of the 22 that completed or were terminated, 5 (23%) have results posted.
This tab as a report to print or save as PDF → With an account.
5 of 26 have an industry lead sponsor. The 10 most frequent:
Muhammad Aamir Latif is the lead sponsor of 58 studies on the registry; 9 are open to participants now.
Muhammad Aamir Latif has 2 studies filed under Macular Edema — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 26 studies testing Triamcinolone Acetonide in Macular Edema, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Local data comparing the effects of intravitreal bevacizumab and posterior sub-Tenon triamcinolone acetonide on central macular thickness (CMT) in patients with diabetic macular edema (DME) are scarce. Therefore, the present study was undertaken to evaluate and compare the short-term anatomical outcomes of these two treatments in terms of CMT reduction.
Although both intravitreal bevacizumab and posterior sub-Tenon triamcinolone acetonide can improve the anatomical outcomes of DME, treatment response may vary according to the route of corticosteroid administration, baseline disease characteristics, and duration of follow-up. Evidence directly comparing these two treatment approaches remains limited, particularly in local clinical settings. Such a comparison may help clarify their relative short-term anatomical effectiveness and provide locally relevant evidence to guide treatment selection in patients with DME.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Patients received an intravitreal injection of bevacizumab 1.25 mg/0.05 mL through the pars plana 3.5-4 mm posterior to the limbus under local anesthesia.
Drug: Bevacizumab Intravitreal Injection
Patients received a posterior sub-Tenon injection of triamcinolone acetonide 1.25 mg under aseptic conditions. The triamcinolone was drawn into a 1-mL syringe and administered using a 26-gauge, 5/8-inch sharp-tipped needle, which was advanced to facilitate deposition within the posterior sub-Tenon space.
Drug: Triamcinolone Acetonide Injection
Patients received an intravitreal injection of bevacizumab 1.25 mg/0.05 mL through the pars plana 3.5-4 mm posterior to the limbus under local anesthesia.
Patients received a posterior sub-Tenon injection of triamcinolone acetonide 1.25 mg under aseptic conditions. The triamcinolone was drawn into a 1-mL syringe and administered using a 26-gauge, 5/8-inch sharp-tipped needle, which was advanced to facilitate deposition within the posterior sub-Tenon space.
Central Macular Thickness
Change in CMT, measured in micrometers (μm), was calculated as baseline CMT minus CMT measured one month after treatment. A positive value indicated a reduction in CMT, whereas a negative value indicated an increase in CMT.
Time frame: 30 days
Plan to share: No — Data can be shared on a reasonable request.
No publications or documents are linked to this record.
Ran from Oct 2025 to primary completion in Jun 2026, 8 months.
Of 47 non-industry interventional studies with no phase under Macular Edema, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 42. This study's 8 months is below that.
Counting every sponsor, half of 51 studies reached it within 18 months; a quarter within 8 and three quarters within 37.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Triamcinolone Acetonide
Muhammad Aamir Latif